Boston Scientific Corporation $BSX Holdings Cut by Arvest Investments Inc.

Arvest Investments Inc. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 77.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,983 shares of the medical equipment provider’s stock after selling 10,008 shares during the quarter. Arvest Investments Inc.’s holdings in Boston Scientific were worth $284,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its position in Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 100 shares in the last quarter. Claret Asset Management Corp increased its stake in Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC raised its position in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 103 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors raised its position in shares of Boston Scientific by 2.3% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock worth $466,000 after buying an additional 108 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $62.73 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 1 year low of $61.24 and a 1 year high of $109.50. The company has a market cap of $93.23 billion, a PE ratio of 32.34, a PEG ratio of 0.97 and a beta of 0.78. The stock’s 50-day moving average price is $74.61 and its two-hundred day moving average price is $89.33.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. Barclays decreased their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Citigroup lowered their price target on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Needham & Company LLC reissued a “buy” rating and issued a $97.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. Finally, JPMorgan Chase & Co. cut their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.